Title:Recent Developments in Tyrosine Kinase Inhibitor-based Nanotherapeutics
for EGFR-resistant Non-small Cell Lung Cancer
Volume: 22
Issue: 3
Author(s): Eknath Kole, Krishna Jadhav, Raghuraj Singh, Shilpa Mandpe, Ashwin Abhang, Rahul K. Verma and Jitendra Naik*
Affiliation:
- Department of Pharmaceutical Technology, University Institute of Chemical Technology, KBC North Maharashtra
University, Jalgaon M.S. 425001, India
Keywords:
Non-small cell lung cancer (NSCLC), tyrosine kinase inhibitor (TKI), epidermal growth factor receptor (EGFR), EGFR-TKI resistance, Combination therapy, Nanoparticles.
Abstract: The advent of drug resistance in response to epidermal growth factor receptor (EGFR)-
tyrosine kinase inhibitor (TKI) targeted therapy represents a serious challenge in the management of
non-small cell lung cancer (NSCLC). These acquired resistance mutations, attributed to several advanced
EGFR mutations and, necessitated the development of new-generation TKIs. Nanomedicine
approaches provide a plausible way to address these problems by providing targeted delivery and
sustained release, which have demonstrated success in preclinical trials. This review article provides a
summary of nano-formulations designed for EGFR-TKI-resistant NSCLC, highlighting their efficacy
in both in vitro and in vivo models. These findings reveal insights into the design of nanoparticles and
multifunctional nanosystems, offering a potential avenue for efficacious treatment of EGFR-TKIresistant
NSCLC.
